Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(17%)
Results Posted
50%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
5
83%

Phase Distribution

1

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
5(83.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Enrolling by invitation1
Withdrawn1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 25 (83.3%)

Trials by Status

enrolling_by_invitation117%
withdrawn117%
completed233%
terminated117%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
enrolling_by_invitationphase_2

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
completedphase_2

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

NCT05983770
recruitingphase_1

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

NCT05027906
terminatedphase_2

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

NCT05125068
completedphase_2

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06126380Phase 2

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Enrolling By Invitation
NCT05983770Phase 2

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Completed
NCT05027906Phase 1

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Recruiting
NCT05125068Phase 2

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Terminated
NCT04322149Phase 2

Multiple Doses of AT-1501-A201 in Adults With ALS

Completed
NCT04711226Phase 2

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6